Luminex, BD combine for cancer diagnostics
This article was originally published in Clinica
Executive Summary
Luminex has partnered with BD Diagnostics’ TriPath subsidiary to develop, market and sell new biomarker-based diagnostic tests for early-stage detection of certain cancers. The two firms have signed a development and supply agreement under which the new technology will be developed using Luminex’s multiplexing xMAP platform. This allows scientists to conduct multiple tests simultaneously on one patient sample. Financial details of the partnership were not revealed. According to Austin, Texas-based Luminex, the survival rate of women diagnosed with ovarian cancer at an early stage is more than 90%, compared to 20-30% when the disease is detected at a later stage.